The Immune Response Corporation Announces Data Safety Monitoring Board Meeting on REMUNE(TM) Phase III Clinical Trial
PR Newswire - June 09, 1998 08:41
IMNR %MTC %PDT V%PRN P%PRN
--------------------------------------------------------------------------------
CARLSBAD, Calif., June 9 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the independent Data Safety Monitoring Board (DSMB) has completed the interim analysis of the 2,500 patient pivotal Phase III clinical endpoint trial using REMUNE. As anticipated, the DSMB recommended the trial continue as currently being conducted. In addition to the Phase III trial, the company is currently conducting a placebo-controlled clinical trial to further examine the effects of REMUNE in subjects concurrently treated with highly active antiviral drug therapy (HAART). It is expected that data on this trial will be presented at the 12th World AIDS Conference in Geneva, Switzerland.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases and cancer. The Company is conducting clinical trials for its immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a targeted delivery technology for gene therapy which is designed to enable the intravenous injection of genes for delivery directly to the liver. The Company's gene therapy program is currently focused on diseases of the liver and is in preclinical studies for the treatment of hemophilia and hepatitis.
NOTE: The Immune Response Corporation news releases are available at no charge through the company's automated attendant 800 number at 800-491-0153. News releases are also available through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE Immune Response Corporation
/CONTACT: Debra L. Altman, Manager of Investor Relations of Immune
Response Corporation, 800-491-0153/
/Company News On-Call: prnewswire.com or fax, 800-758-5804,
ext. 434675/
/Web site: imnr.com
(IMNR)
CO: Immune Response Corporation
ST: California
IN: MTC
SU: PDT
|
